TY - JOUR T1 - Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. AU - Tray,Nancy, AU - Weber,Jeffrey S, AU - Adams,Sylvia, PY - 2018/10/4/entrez PY - 2018/10/4/pubmed PY - 2019/8/29/medline SP - 1122 EP - 1128 JF - Cancer immunology research JO - Cancer Immunol Res VL - 6 IS - 10 N2 - Immune-checkpoint blockade (ICB), in particular PD-1 inhibition, has rapidly changed the treatment landscape and altered therapeutic paradigms across many tumor types, with unprecedented rates of durable clinical responses in a number of cancers. Despite this success, only a subset of patients responds to ICB and, as a result, predictive biomarkers would be useful to guide the selection of patients for these therapies. This article highlights currently used biomarkers, as well as several promising novel candidates, and also discusses the challenges involved in establishing their analytic validity and clinical utility. Progress is being evaluated in melanoma and non-small cell lung cancer, for which PD-1 ± CTLA-4 inhibitors have become standard therapy, to other malignancies for which PD-L1 inhibitors remain investigational. Although single biomarkers have substantial limitations, a combination of biomarkers that reflect the interaction of host and tumor will likely be needed to provide a reproducible surrogate for the benefit of checkpoint modulation. Cancer Immunol Res; 6(10); 1122-8. ©2018 AACR. SN - 2326-6074 UR - https://www.unboundmedicine.com/medline/citation/30279188/Predictive_Biomarkers_for_Checkpoint_Immunotherapy:_Current_Status_and_Challenges_for_Clinical_Application_ DB - PRIME DP - Unbound Medicine ER -